News room

Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment

Press releases

2020

30 March, 2020 PledPharma’s 2019 annual report published News Corporate Information Other Corporate Information English Regulatory Listing Regulation IR Optional
25 March, 2020 KALLELSE TILL ÅRSSTÄMMA I PLEDPHARMA AB News Corporate Information General meeting Notice English Regulatory Listing Regulation IR Optional
1 March, 2020 PledPharma places dosing of patients in the POLAR program on hold News Corporate Information Other Corporate Information English Regulatory MAR IR Optional mfn-cus-pledox
18 February, 2020 Year-end report January-December 2019 News English Regulatory MAR Report Interim Yearend IR Optional
23 January, 2020 PledPharma provides update on the clinical POLAR program, clinical hold in the US News Corporate Information Other Corporate Information English Regulatory MAR IR Optional mfn-cus-pledox
Previous

Calendar and upcoming reports

April 15, 2024
Annual Report 2023

May 3, 2024
Interim Report Q1 2024 (7:00am CEST)

Show more events

Share

Twitter
LinkedIn

Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10

E-mail: info@egetis.com

Cookies
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept all”, you consent to the use of ALL the cookies. However, you may visit "Settings" to provide a controlled consent. Read our cookie policy
Settings Accept all
Cookies
Choose what kind of cookies to accept. Your choice will be saved for one year. Read our cookie policy
Save Accept all